此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

韩国对2型糖尿病中OAD三重治疗的安全性和有效性的研究 (TRIO)

2026年9月29日 更新者:Chong Kun Dang Pharmaceutical

一项多中心,前瞻性,非差异观察研究,以评估OAD三重治疗在韩国2型糖尿病患者中的安全性和有效性

A multicenter, prospective, non-interventional observation study to evaluate the safety and effectiveness of OAD triple therapy in Korean Type 2 diabetic mellitus patients.

研究概览

详细说明

The study was designed as a multicenter, prospective, non-interventional, observational study in patients with type 2 diabetes mellitus who had inadequate glycemic control with conventional combination oral hypoglycemic agents including metformin.

Participants in this study will have type 2 diabetes mellitus with insufficient glycemic control on conventional combination therapy with a DPP-4i or SGLT2i oral hypoglycemic agent, including metformin, requiring the addition of one of the following: SGLT-2i, DPP-4i, or TZD.

The 3-drug combination therapy will be prescribed to subjects based on the medical judgment of the investigator based on the licensure of SGLT-2i, DPP-4i, or TZD(efficacy, dosing, precautions for use, etc.) in a real-world practice setting and all treatment and observation, including administration of medications and laboratory tests, will be based on the medical judgment of the investigator.

研究类型

观察性的

注册 (估计的)

10000

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Soo Lim, M.D, Ph.D.
  • 电话号码:82-2-6373-0773
  • 邮箱:limsoo@snu.ac.kr

学习地点

    • Gyeonggi-do
      • Seongnam-si、Gyeonggi-do、韩国
        • 招聘中
        • Seoul National University Bundang Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

19年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Patients with type 2 diabetes mellitus whose glycemic control is inadequate on 2 oral hypoglycemic agents, including metformin.

描述

Inclusion Criteria:

  1. Patients with type 2 diabetes who are 19 years of age or older at the time of enrollment.
  2. Continued DPP-4i or SGLT-2i oral hypoglycemic combination therapy with metformin for at least 8 weeks prior to enrollment.
  3. 7.0% ≤ HbA1c < 10.0% based on laboratory tests performed within 4 weeks of enrollment.
  4. Voluntarily give written informed consent after being told about the study.

Exclusion Criteria:

  1. Patients with type 1 diabetes and secondary diabetes.
  2. Patients receiving concomitant therapy with 3 or more oral hypoglycemic agents within 8 weeks of enrollment.
  3. Requiring treatment with insulin, GLP-1, etc. in addition to oral hypoglycemic agents during the study.
  4. End-stage renal disease and hemodialysis patients.
  5. diabetic ketoacidosis Patients.
  6. Pregnant and lactating women.
  7. Patients who are contraindicated by any of the "Precautions for Use" in the license for the drug being administered during the study, given the observational nature of the study under routine practice.
  8. Patients with a history of hypersensitivity to the investigational drug or any of its components or excipients.
  9. Anyone else deemed by the investigator to be unsuitable for participation in the study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Metformin/DPP4i/SGLT2i

Metformin + DPP4i 2-drug combination plus one of the SGLT-2i class of drugs.

SGLT2 inhibitor class of drugs

DPP4 inhibitor class of drugs

Metformin/DPP4i/TZD

Metformin + DPP4i 2-drug combination plus one of the TZD class of drugs.

DPP4 inhibitor class of drugs

Thiazolidinedione class of drugs

Metformin/SGLT2i/DPP4i

Metformin + SGLT2i 2-drug combination plus one of the DPP4i class of drugs.

SGLT2 inhibitor class of drugs

DPP4 inhibitor class of drugs

Metformin/SGLT2i/TZD

Metformin + SGLT2i 2-drug combination plus one of the TZD class of drugs.

SGLT2 inhibitor class of drugs

Thiazolidinedione class of drugs

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Safety Evaluation of Triple Combination Therapy with SGLT-2i, DPP-4i, or TZD Class Drugs, Including Metformin
大体时间:Up to 24 months

Safety will be assessed based on all adverse events, laboratory test results, and vital signs collected after enrollment during the study period.

Up to 24 months

次要结果测量

结果测量
措施说明
大体时间
Changes in HbA1c
大体时间:3, 6, (9), 12, 18, and 24 months

Evaluation of HbA1c(%) Change Compared to Baseline in Each Combination Group

3, 6, (9), 12, 18, and 24 months
Changes in FPG
大体时间:3, 6, (9), 12, 18, and 24 months

Evaluation of FPG(mg/dL) Change Compared to Baseline in Each Combination Group

3, 6, (9), 12, 18, and 24 months
Percentage of Subjects with HbA1c < 7.0%
大体时间:3, 6, (9), 12, 18, and 24 months

Percentage of Subjects with HbA1c < 7.0% in Each Combination Group

3, 6, (9), 12, 18, and 24 months
Percentage of Subjects with HbA1c < 6.5%
大体时间:3, 6, (9), 12, 18, and 24 months

Percentage of Subjects with HbA1c < 6.5% in Each Combination Group

3, 6, (9), 12, 18, and 24 months
Factors influencing HbA1c change at each time point in each combination group.
大体时间:3, 6, (9), 12, 18, and 24 months

demographics, previous hypoglycemic medications, hypoglycemic medication components and doses, duration of hypoglycemic medication, duration of disease, comorbidities, concomitant medications, etc.

3, 6, (9), 12, 18, and 24 months

其他结果措施

结果测量
措施说明
大体时间
Changes in Weight
大体时间:3, 6, (9), 12, 18, 24 months

Changes in Weight(kg) Compared to Baseline in Each Combination Group

3, 6, (9), 12, 18, 24 months
Changes in waist circumference
大体时间:12 and 24 months

Changes in waist circumference(cm) compared to Baseline in Each Combination Group

12 and 24 months
Changes in body composition(protein mass)
大体时间:12 and 24 months

Change in total protein mass from baseline in each combination group, as measured using InBody 770 or a higher model.

12 and 24 months
Changes in body composition(protein mass)
大体时间:12 and 24 months

Change in protein mass from baseline in each combination group, as measured using InBody 770 or a higher model.

12 and 24 months
Changes in body composition(body fat)
大体时间:12 and 24 months

Change in body fat mass from baseline in each combination group, as measured using InBody 770 or a higher model.

12 and 24 months
Changes in body composition(mineral mass)
大体时间:12 and 24 months

Change in mineral mass from baseline in each combination group, as measured using InBody 770 or a higher model.

12 and 24 months
Changes in Fatty Liver Index
大体时间:6, 12, 18, and 24 months

Changes in Fatty Liver Index compared to Baseline in Each Combination Group

6, 12, 18, and 24 months
Changes in AST
大体时间:6, 12, 18, and 24 months

Changes in AST(IU/L) Compared to Baseline in Each Combination Group

6, 12, 18, and 24 months
Changes in ALT
大体时间:6, 12, 18, and 24 months

Changes in ALT(IU/L) Compared to Baseline in Each Combination Group

6, 12, 18, and 24 months
Changes Platelet Levels
大体时间:6, 12, 18, and 24 months

Changes in Platelet(10^3/uL) Levels Compared to Baseline in Each Combination Group

6, 12, 18, and 24 months
Changes in Blood Lipid Levels(Total cholesterol, LDL-C, HDL-C, TG)
大体时间:6, 12, 18, and 24 months

Change in Total cholesterol, LDL-C, HDL-C, TG(mg/dL) compared to Baseline in Each Combination Group

6, 12, 18, and 24 months
Changes in Insulin-Related Test Levels(HOMA-IR)
大体时间:12 and 24 months

Changes in HOMA-IR compared to Baseline in Each Combination Group

12 and 24 months
Changes in Insulin-Related Test Levels(HOMA-β)
大体时间:12 and 24 months

Changes in HOMA-β(%) compared to Baseline in Each Combination Group

12 and 24 months
Changes in eGFR
大体时间:6, 12, 18, and 24 months

Changes in eGFR(mL/min/1.73m2) compared to Baseline in Each Combination Group

6, 12, 18, and 24 months
Changes in UACR
大体时间:6, 12, 18, and 24 months

Changes in UACR(mg/g) compared to Baseline in Each Combination Group

6, 12, 18, and 24 months
Change in hsCRP
大体时间:12 and 24 months

Change in hsCRP(mg/dL) compared to Baseline in Each Combination Group

12 and 24 months
Change in ProBNP(or NT-ProBNP)
大体时间:12 and 24 months

Change in ProBNP(or NT-ProBNP)(pg/mL) compared to Baseline in Each Combination Group

12 and 24 months
Change in PP2 Compared to Baseline in Each Combination Group
大体时间:3, 6, (9), 12, 18, and 24 months

Change in PP2(mg/dL) compared to Baseline in Each Combination Group.

3, 6, (9), 12, 18, and 24 months
Incidence Rate of Major Adverse Cardiovascular Events(MACE)
大体时间:24 month

Incidence Rate of Major Adverse Cardiovascular Events(MACE) from Baseline to 24 Months for Each Combination Group

24 month
Incidence Rate of Diabetic Microvascular Events
大体时间:24 month

Incidence Rate of Diabetic Microvascular Events from Baseline to 24 Months for Each Combination Group

24 month

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年1月2日

初级完成 (估计的)

2028年10月1日

研究完成 (估计的)

2029年12月31日

研究注册日期

首次提交

2024年6月30日

首先提交符合 QC 标准的

2025年2月18日

首次发布 (实际的)

2025年2月20日

研究记录更新

最后更新发布 (实际的)

2026年9月30日

上次提交的符合 QC 标准的更新

2026年9月29日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅